Search - tctmd.com

Displaying 1 - 7 of 7

Sort: Relevancy | Date

Presentation ESC 2021

Cardiovascular Safety of Degarelix versus Leuprolide in Patients with Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial

Presenter: Renato D. Lopes

August 31, 2021

Presentation ESC 2021

Primary Outcomes of the Amplatzer Amulet IDE Randomized Controlled Trial

Presenter: Dhanunjaya Lakkireddy

August 31, 2021

Presentation ESC 2021

One-month Dual Antiplatelet Therapy Followed by Clopidogrel Monotherapy in Acute Coronary Syndrome:

Presenter: Hirotoshi Watanabe

August 31, 2021

Presentation ESC 2021

Influenza Vaccination after Myocardial Infarction - a randomized, double-blind, placebo-controlled, multicenter trial

Presenter: Ole Fröbert

August 31, 2021

Presentation ESC 2021

Implantable Loop Recorder to Detect Atrial Fibrillation and Prevent Stroke (The LOOP Study): A Randomised Controlled Trial

Presenter: Jesper Hastrup Svendsen

August 31, 2021

Presentation ESC 2021

Continuing versus Suspending Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers:Impact on Adverse Outcomes in Hospitalized Patients with Severe Acute Respiratory Distress Syndrome Coronavirus 2 (SARS-CoV-2

Presenter: Renato D. Lopes

August 30, 2021

Presentation ESC 2021

Medically Ill Hospitalized Patients For COVID –19 Thrombosis Extended Prophylaxis With Rivaroxaban Therapy: THE MICHELLE TRIAL

Presenter: Eduardo Ramacciotti

August 30, 2021

Advertisement

Cardiovascular Safety of Degarelix versus Leuprolide in Patients with Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial

Primary Outcomes of the Amplatzer Amulet IDE Randomized Controlled Trial

One-month Dual Antiplatelet Therapy Followed by Clopidogrel Monotherapy in Acute Coronary Syndrome:

Influenza Vaccination after Myocardial Infarction - a randomized, double-blind, placebo-controlled, multicenter trial

Implantable Loop Recorder to Detect Atrial Fibrillation and Prevent Stroke (The LOOP Study): A Randomised Controlled Trial

Continuing versus Suspending Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers:Impact on Adverse Outcomes in Hospitalized Patients with Severe Acute Respiratory Distress Syndrome Coronavirus 2 (SARS-CoV-2

Medically Ill Hospitalized Patients For COVID –19 Thrombosis Extended Prophylaxis With Rivaroxaban Therapy: THE MICHELLE TRIAL

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content